Clinical trial

A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of Xanomeline and Trospium Chloride Capsules (KarXT) in the Treatment of Chinese Adult Participants With Schizophrenia

NCT07802132

StatusNOT_YET_RECRUITING

Study typeOBSERVATIONAL

Start date2026-09-20

PhaseN/A

Study timeline

Study start (estimated)2026-09-20Date precision: day

Registry last updated2026-09-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophrenia Disorderunresolved

Interventions

Xanomeline and trospium chloride (KarXT)DRUG

Sponsors & collaborators

Zai Lab (Shanghai) Co., Ltd.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07802132 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.